大黄酸和吡格列酮对实验性大鼠非酒精性脂肪性肝炎治疗作用的比较

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (4): 397-400.

大黄酸和吡格列酮对实验性大鼠非酒精性脂肪性肝炎治疗作用的比较

应卫星¹, 朱畴文², 李荣洲¹

¹温州医学院附属第三医院消化科, 温州325200, 浙江;
²复旦大学附属中山医院消化科, 上海200032

收稿日期:2009-02-20 修回日期:2009-04-13 发布日期:2020-10-29
通讯作者: 李荣洲,男,主任医师,研究方向:脂肪肝及胃肠道肿瘤的诊治。Tel:13705781365 E-mail:lirongzhou761122@126.com
作者简介:应卫星,男,硕士,主治医师,研究方向:脂肪肝及胃肠道肿瘤。Tel:13967754472 E-mail:yingwx@126.com
基金资助:
浙江省医药卫生科学研究基金计划(2007B208);瑞安市科技计划项目基金资助(20072162)

Comparion between therapeutic effects of rhein and pioglitazone on experimental nonalcoholic steatosis hepatitis rats

YING Wei-xing¹, ZHU Chou-wen²,LI Rong-zhou¹

¹Department of Gastroenterology Third Affiliated Hospital of Wenzhou Medical College, Wenzhou 325200, Zhejiang, China;
²Department of Gastroenterolog Zhongshan Hospitaal Fudan University, Shanghai 200032, China

Received:2009-02-20 Revised:2009-04-13 Published:2020-10-29

摘要/Abstract

摘要： 目的: 探讨大黄酸和吡格列酮各自对高脂诱建的大鼠非酒精性脂肪性肝炎(NASH)的影响及其可能的机制。方法: 52只清洁级雄性SD大鼠,体重140～160g,随机分成4组:对照组(n=14)、模型组(n=14)、大黄酸组(n=12)、吡格列酮组(n=12)。模型组由高脂高胆固醇饲料(普通饲料+10%猪油+2%胆固醇配制)喂养,药物组均在12周高脂饮食后即造模成功后给予干预。大黄酸用生理盐水配成5g/L混悬液,每天固定时间100mg/kg^-1/d^-1灌胃,吡格列酮组8mg/kg^-1/d^-1灌胃。于第20周处死。测定所有动物体重、肝湿重、计算肝指数;测定空腹血糖(FBG)、转氨酶及血脂水平;放射免疫法测空腹胰岛素(FINS)及TNF-α,计算胰岛素抵抗指数;酶法测定肝组织匀浆丙二醛(MDA)、谷胱甘肽过氧物酶(GSH-Px)水平;HE染色肝病理组织切片。结果: 与模型组相比,药物组ALT、AST、血糖、胰岛素及胰岛素抵抗指数、TNF-α、MDA有明显下降;大黄酸组肝脂肪变较吡格列酮组明显(P<0.05),但其肝内炎症较吡格列酮组轻。结论: 大黄酸和吡格列酮对大鼠NASH均有治疗作用,但在改善肝脂肪变及炎症方面有所不同。

关键词: 非酒精性脂肪性肝炎, 大黄酸, 吡格列酮, 胰岛素抵抗, 脂质代谢紊乱

Abstract: AIM: To approach the therapeutic effect of rhein and pioglitazone respectively on nonalcoholic steatosis hepatitis(NASH)rats and the possible mechanism.METHODS: 52 male SD rats were randomly divided into 4 groups :control group (n=14), model group (n=14), rhein group (n=12), piogli-tazone group (n=12), the body weight were 140 -160 g.Control group were fed with normal diet for 20 weeks (2 rats for 12 weeks and then were executed).Model group were fed with high-fat and high-cholesterol diet consisting of normal diet , 10 %lard and 2 %cholesterol , for 20 weeks (2 rats for 12 weeks and then were executed).Drugs were given after 12 weeks fed with high-fat and high-cholesterol diet.Rhein (5 g/L suspension)was prepared with normal saline , intragastric administration(100 mg/kg^-1?d-1) every day in fixation time.Pioglitazone group (8 mg/kg^-1 ?d^-1)were intragastric administered.All rats were executed after 20 weeks , and the body weight , liver humid weight were determined , the liver index number was calculated.The levels of fasting blood glucose(FBG), aminopherase and blood fat were determined.The fasting insulin (FINS)and TNF-αwere measured by radio-immunoassay , the insulin resistance index was calculated.The levels of malonaldehyde(MDA), glutathione peroxidase(GSH-Px)in hepatic tissue bomogenate were measured using enzymic method , the liver histopathologic slides were dyed with HE dyeing.RESULTS: Compared with model group , the levels of ALT , AST , blood glucose , insuline , insulin resistance index , TNF-α, MDA were obviously decreased in drug groups.Compared with pioglitazone group , the hepatic steatosis in rhein was obvious(P<0.05), but the inflammation in liver was lower grade.CONCLUSION: Rehin and pioglitazone have therapeutical effects on NASH rats.However , they are different in the aspects of improving hepatocyte steatosis and inflammatory.

Key words: nonalcoholic steatosis hepatitis, rhein, pioglitazone, insulin resistance, fatty substance metabolic disorder

中图分类号:

R965.2

应卫星, 朱畴文, 李荣洲. 大黄酸和吡格列酮对实验性大鼠非酒精性脂肪性肝炎治疗作用的比较[J]. 中国临床药理学与治疗学, 2009, 14(4): 397-400.

YING Wei-xing, ZHU Chou-wen,LI Rong-zhou. Comparion between therapeutic effects of rhein and pioglitazone on experimental nonalcoholic steatosis hepatitis rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 397-400.

[1]	蔡祖欢, 邓桃妹, 魏奶杰, 朱丹, 钱斐, 王广基, 张经纬. 水飞蓟宾改善非酒精性脂肪性肝炎小鼠脂质代谢紊乱[J]. 中国临床药理学与治疗学, 2023, 28(3): 241-248.
[2]	全海燕, 江兴, 何璐. 线粒体自噬在肝胰岛素抵抗中作用机制的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(2): 198-204.
[3]	全海燕，刘玉环，杨丽，阳芳，秦旭平. CGRP通过激活cAMP/PPARγ/eNOS途径改善血管内皮细胞胰岛素抵抗[J]. 中国临床药理学与治疗学, 2019, 24(6): 615-622.
[4]	丁凡，李文雄，张佳莉，张岩. 糖尿病性肌少症发病机制和治疗靶点的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(12): 1428-1433.
[5]	郑丽，莫娟芬，吴加元，郭丽，鲍轶. 基于网络药理学的虎杖抗高血脂作用及信号通路研究[J]. 中国临床药理学与治疗学, 2019, 24(10): 1107-1119.
[6]	宋美情. 二甲双胍对2型糖尿病伴高血压患者骨密度及胰岛素抵抗、细胞因子的影响[J]. 中国临床药理学与治疗学, 2017, 22(6): 694-698.
[7]	刘晓颖, 蔡诗婷, 杨敏, 萧定璋, 谭红红, 陈景, 陈少贤, 陈红梅, 杨慧, 余细勇. TLR2/NLRC5参与棕榈酸诱导的心肌细胞凋亡及相关机制研究[J]. 中国临床药理学与治疗学, 2015, 20(7): 763-768.
[8]	沈纪中, 柳航. 高糖饮水诱导代谢综合征小鼠模型的实验研究[J]. 中国临床药理学与治疗学, 2014, 19(9): 1011-1015.
[9]	邹柳义, 王美荣, 倪连松. 酮替芬对高糖高脂饮食大鼠胰岛素抵抗的干预研究[J]. 中国临床药理学与治疗学, 2014, 19(7): 761-765.
[10]	蔡兆斌, 王福根, 庄让笑, 方红英, 邵益丹, 席建军, 潘旭旺, 史婷婷, 梁伟峰. 乙酰半胱氨酸牛磺酸镁盐对非酒精性脂肪性肝炎大鼠脂质代谢的影响[J]. 中国临床药理学与治疗学, 2014, 19(11): 1206-1210.
[11]	张妍, 袁鹤鸣, 韩真. 吡格列酮改善代谢综合征大鼠肝脏氧化和硝化应激[J]. 中国临床药理学与治疗学, 2013, 18(9): 988-992.
[12]	蒋励, 贺碧霞, 丁启龙. 甲状腺激素和肝脏胰岛素抵抗的研究进展[J]. 中国临床药理学与治疗学, 2013, 18(3): 356-360.
[13]	何春玲, 邢文, 鲁柯兵, 夏礼斌, 王安才. 吡格列酮联用阿托伐他汀对2型糖尿病患者血脂及血管内皮功能的影响[J]. 中国临床药理学与治疗学, 2013, 18(2): 198-201.
[14]	宋婧, 吴平, 王锡梅. 内脂素与妊娠期糖尿病相关性研究[J]. 中国临床药理学与治疗学, 2013, 18(12): 1406-1409.
[15]	黎小妍, 张平, 陶玲, 刘玉兴. 坎地沙坦对自发性高血压大鼠胰岛素抵抗及血清脂联素的影响[J]. 中国临床药理学与治疗学, 2013, 18(11): 1201-1204.